Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Bioxytran, Inc.
- Market Cap
- Unavailable
- Price
- $0.02131
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.34%
- Volume
- 156.6K
About
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Quick stats
Shares outstanding—
Computed float83.4M
Float / sharesUnknown
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001445815
Websitehttps://www.bioxytraninc.com
AI Summary
AI-generated1/5
minorbullishclinical trial
Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence
Bioxytran reported positive clinical observations from the first CIDP patient treated with its investigational drug PLICID, noting improvements in finger function and walking ability with no adverse events.
PLICID is a galectin antagonist designed using the company's proprietary ASI-driven platform, developed with researchers at the University of Minnesota.
Management emphasized that observations from a single patient are insufficient to establish safety or efficacy but intend to pursue further evaluation in a larger population.
Red flags
- observations based on a single patient (n=1) are insufficient to establish safety or efficacy